Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
Semaglutide mimics GLP-1, a naturally occurring hormone released after eating. It works through appetite suppression and improved insulin sensitivity, not anabolic pathways. FDA-approved for weight management with extensive safety data. Does not affect muscle building, testosterone, or athletic performance directly. Rated 3 as it is a legitimate prescription medication working through natural satiety pathways rather than performance enhancement.
Overview
A GLP-1 receptor agonist used for weight loss, appetite suppression, and type 2 diabetes management. Originally developed and approved as Ozempic for diabetes, the same drug is now FDA-approved as Wegovy for chronic weight management (injectable and, since December 2025, an oral tablet) and as Rybelsus for oral diabetes treatment. Also carries FDA approvals for reducing major cardiovascular events (SELECT trial) and slowing chronic kidney disease progression in type 2 diabetics (FLOW trial).
Important Warnings
- •BOXED WARNING: Risk of thyroid C-cell tumors observed in rodent studies at clinically relevant exposures; whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans has not been determined. Contraindicated with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- •Can cause muscle loss if protein intake is inadequate
- •Significant rebound weight gain common after discontinuation
- •Roughly a quarter to nearly half of weight lost can be lean mass without resistance training + protein
- •Can cause acute kidney injury, usually via dehydration from GI side effects (nausea, vomiting, diarrhea)
- •Not recommended in patients with severe gastroparesis; concurrent use with another semaglutide-containing product or any other GLP-1 receptor agonist (e.g. tirzepatide) is not recommended
- •Acute pancreatitis and acute gallbladder disease (cholelithiasis/cholecystitis) have been reported
Purpose & Use Cases
Appetite Suppression
Dramatically reduces hunger and food cravings.
Weight Loss
Promotes significant weight loss through reduced caloric intake.
Metabolic Health
Improves insulin sensitivity and blood sugar control.
Benefits
- Significant appetite reduction
- Substantial weight loss (~15% at 68 weeks in STEP 1)
- Improved blood sugar control
- Once-weekly dosing (injectable forms)
- FDA-approved with extensive safety data
- Reduces major cardiovascular events (MACE) in adults with established CV disease and obesity/overweight (SELECT trial)
- Slows chronic kidney disease progression in type 2 diabetics (FLOW trial)
Good to Know
A big chunk of the weight lost is muscle unless you fight for it
Because semaglutide works by cutting appetite, people eat less of everything, including protein, during fast weight loss. Body-composition data (STEP 1 substudy) show roughly 25-45% of total weight lost can come from lean tissue. That is normal for rapid loss, but for a physique it is the whole problem: resistance training plus high protein cuts that lean-mass loss toward zero. For the natty scale, the muscle you keep is the muscle you defended.
GI side effects are the dose-limiter, and mostly self-inflicted by eating too much
Nausea, vomiting and constipation are worst during titration and when you overeat past the (now much earlier) fullness signal. Slow titration, smaller meals and stopping when satisfied prevent most of it. Rushing dose increases to lose faster is the classic mistake.
The weight comes back if you just stop. It is a long-term tool
Appetite and weight rebound after discontinuation; the STEP 1 extension saw participants regain about two-thirds of lost weight within a year off-drug. Treat it as long-term therapy or a slow, habit-locking off-ramp, not a short "cycle", otherwise the loss reverses.
Not anabolic, not banned: but muscle protection is entirely on you
Semaglutide works through satiety and glucose control, not any performance pathway, and it is not on the WADA Prohibited List. It is a legitimate cutting aid, but it does nothing to build or hold muscle, that job falls to your training and protein.
Dosage Guidelines
| Route | Typical Dose | Frequency | Cycle |
|---|---|---|---|
| Subcutaneous (Ozempic/Wegovy) | 1 – 1.7 mg/week | Once weekly subcutaneous injection | 12 – 52 wk |
| Oral tablet (Rybelsus / Ozempic Tablets / Wegovy Tablets) | 7 – 14 mg/day | Once daily, swallowed whole on an empty stomach first thing in the morning with up to 4oz (120mL) of plain water only; wait at least 30 minutes before eating, drinking anything else, or taking other oral medications | 12 – 52 wk |
Dosing depends on how it's administered. Pick your route in the calculator to score the one you use.
FDA titration schedule is fixed at 4-week steps: 0.25mg (weeks 1-4, sub-therapeutic/tolerability dose) -> 0.5mg (weeks 5-8) -> 1mg (weeks 9-12) -> 1.7mg (weeks 13-16) -> 2.4mg maintenance (week 17+, the recommended Wegovy weight-loss target; 1.7mg is the alternate maintenance dose if 2.4mg is not tolerated). Ozempic (type 2 diabetes indication) maintenance tops out lower, at 0.5mg, 1mg, or 2mg once weekly. A newer higher-dose option, Wegovy 7.2mg ("Wegovy HD"), was added to the label for patients with insufficient response after at least 4 weeks at 2.4mg - real and FDA-approved, but not yet a typical/common dose in practice as of mid-2026. Oral tablet forms exist too and are dosed daily, not weekly: Rybelsus (diabetes, titrated up to 14mg/day) and, since December 2025, an oral Wegovy tablet for weight loss (titrated 1.5mg -> 4mg -> 9mg -> 25mg once daily).
Confirmed directly from current FDA Prescribing Information PDFs (rev. 1/2026 for Rybelsus/Ozempic Tablets; rev. 06/2026 for Wegovy Tablets). Oral bioavailability is very low (~0.4-1%) because semaglutide is a peptide that GI enzymes/acid would otherwise destroy; tablets are co-formulated with the absorption enhancer SNAC, which is why the strict empty-stomach/minimal-water/30-min-wait administration rules exist -- breaking them meaningfully blunts absorption.
Side Effects
Nausea
very commonNausea is the most common side effect, especially during dose titration.
Slow titration; eat smaller meals; avoid fatty foods.
Vomiting
commonCan occur especially with rapid dose increases or overeating.
Slow titration; stop eating when satisfied.
Diarrhea
very commonReported in roughly 30% of patients at the 2.4mg weight-loss dose (FDA trial data), on par with constipation and second only to nausea in frequency.
Usually transient; stay well hydrated and monitor electrolytes.
Ozempic Face
commonFacial fat loss causing a gaunt, aged appearance.
Maintain adequate protein intake; slower weight loss.
Constipation
commonSlowed GI motility can cause constipation.
Fiber supplementation; adequate hydration.
Gallbladder Issues
uncommonRapid weight loss can increase gallstone risk. Cholelithiasis reported in ~1.6% of Wegovy injection users vs 0.7% on placebo.
Adequate fat intake; monitor for symptoms.
Acute Pancreatitis
rareRare but serious, including fatal and non-fatal hemorrhagic/necrotizing cases; observed with GLP-1 receptor agonists including semaglutide. Watch for persistent, severe abdominal pain (may radiate to the back), with or without nausea/vomiting.
Discontinue immediately and seek medical care if suspected. Not recommended in patients with a history of pancreatitis.
General Mitigation Strategies
Very slow titration over months. High protein intake to minimize muscle loss. Adequate fiber and hydration. Stop eating when satisfied - overeating causes severe nausea.
Support Supplements
Ancillary supplements commonly run alongside Semaglutide to manage side effects, support the target tissue, or fill nutrient demands it creates.
High protein intake
KeyThe central defense against lean-mass loss. On GLP-1s, appetite crashes and total intake drops, so protein is usually the first thing to fall short, deliberately hitting a high target protects muscle during rapid weight loss.
- Dose
- 1.2-2.0 g/kg bodyweight per day (aim toward the higher end if lifting)
- Timing
- Spread across meals; a protein shake helps when appetite is suppressed
Resistance training
KeyThe other half of muscle preservation. Trials show combining a GLP-1 with resistance training plus adequate protein cuts lean-mass loss toward near-zero, versus ~25-45% of weight lost coming from lean tissue with the drug alone.
- Dose
- 2-4 sessions/week of progressive resistance work
- Timing
- Throughout the weight-loss phase
Creatine monohydrate
Supports strength and lean-mass retention during a deficit; cheap, well-evidenced and synergistic with the resistance-training stimulus.
- Dose
- 3-5g/day
- Timing
- Daily, any time
Fiber + hydration (and electrolytes)
Slowed gastric emptying plus reduced food/fluid intake commonly cause constipation and dehydration. Fiber, fluids and electrolytes address the most common day-to-day GI complaints.
- Dose
- Adequate dietary/supplemental fiber; deliberate fluid and electrolyte intake
- Timing
- Daily
Post Cycle Therapy (PCT)
Not hormonal. No PCT required.
How It Works
Semaglutide mimics the GLP-1 hormone, which is released after eating. It signals the brain to feel full, slows gastric emptying, and reduces appetite. Also improves insulin sensitivity and blood glucose control.
Fundamentals
Reference on the practices relevant to Semaglutide: how they are done and where they go wrong. Not a recommendation to use it.
Legal Status
FDA-approved prescription medication (USA). Ozempic (injectable, type 2 diabetes, Dec 2017), Rybelsus (oral, type 2 diabetes, Sept 2019), Wegovy (injectable, chronic weight management, June 2021; oral Wegovy tablet, Dec 2025).
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Semaglutide (Ozempic/Wegovy) is not currently listed on the WADA Prohibited List. It is an FDA-approved prescription medication for diabetes and weight management.
References
- Wilding et al., STEP 1 semaglutide weight-loss RCT (NEJM)
- O'Neil & Rubino: Wider benefits of semaglutide across the STEP program, incl. body composition (Postgrad Med, 2022)
- Wilding et al., STEP 1 extension: weight regain and cardiometabolic effects after withdrawal
- Lincoff et al., SELECT trial: semaglutide and cardiovascular outcomes in obesity without diabetes (NEJM 2023)
- Perkovic et al., FLOW trial: semaglutide effects on chronic kidney disease in type 2 diabetes (NEJM 2024)
- Wegovy (semaglutide) FDA Prescribing Information
- Ozempic (semaglutide) FDA Prescribing Information